Lipid 8

Lipid 8 iLNPs were used to
deliver CRISPR-Cas9 mRNA and sgRNA which targeted to the
PLK1 gene. The safety and excellent intracerebral diffusion
performance of lipid 8 iLNPs ensured that the survival of
murine glioblastoma multiforme (GBM) mice was extended.
The median survival was extended by approximately 50% and
the overall survival was increased by 30%. The treatment of
metastatic adenocarcinoma was executed by the EGFRtargeted
lipid 8 iLNPs. These iLNPs possessed the ability of
tumor targeting, which could increase the accumulation of
CRISPR-Cas9 mRNA and sgRNA within the tumor cells.
After a single intraperitoneal administration, 80% PLK1 gene
was edited and the overall survival of mice with high-grade
ovarian cancer malignant ascites was enhanced by 80%
. These results demonstrate the clinical potential
of CRISPR-Cas9 gene editing system can be delivered by
iLNPs for treating tumors, and provide new ideas for tumor
gene therapy.